Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: What every transplanter needs to know

Bone Marrow Transplantation

Volumn 33, Issue 2, 2004, Pages 137-152

  Leather, H L ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Azoles; Cyclosporine; CYP3A4; Cytochrome P450; Drug interactions; Pharmacokinetic; Tacrolimus

Indexed keywords

AMLODIPINE; ASTEMIZOLE; ATORVASTATIN; BENZODIAZEPINE DERIVATIVE; CALCINEURIN INHIBITOR; CARBAMAZEPINE; CASPOFUNGIN; CHLORAMPHENICOL; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DILTIAZEM; FLUCONAZOLE; GLYCOPROTEIN P; ITRACONAZOLE; MIDAZOLAM; OMEPRAZOLE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; SIMVASTATIN; TACROLIMUS; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; VORICONAZOLE;

CLINICAL PRACTICE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME INHIBITION; ENZYME METABOLISM; FOOD DRUG INTERACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; RECIPIENT; SEDATION; SHORT SURVEY; SIDE EFFECT; TACHYCARDIA; TREATMENT FAILURE;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0842345617     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704316     Document Type: Short Survey

References (145)

1. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
2. Flockhart DA. Cytochrome P450 drug interaction table (online). Available from URL: http://medicine.iupui.edu/flockhart/ (accessed October 22, 2002).
3. Watkins PB. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin Liver Dis 1990; 10: 235-250.
4. Pea F, Farlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40: 833-868.
5. Wingard JR, Nash RA, Przepiorka D et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 157-163.
6. Przepiorka D, Nash RA, Wingard JR et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. Biol Blood Marrow Transplant 1999; 5: 94-97.
7. Lampen A, Christians V, Guengerich FP et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23: 1315-1324.
8. Christians U, Jacobsen W, Benet LZ et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-851.
9. Osowski CL, Dix SP, Lin L et al. Evaluation of the drug interaction between high dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268-1272.
10. Manez R, Martin M, Raman D et al. Fluconazole therapy in transplant recipients receiving FK506. Transplantation 1994; 57: 1521-1523.
11. Leather HL, Wingard JR. Characterizing the pharmacokinetic (PK) drug interaction between intravenous (IV) itraconazole (ITRA) and IV tacrolimus (FK506) or IV cyclosporine (CyA) in allogeneic bone marrow transplant (alloBMT) patients. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16-19 December 2001 (abstract A-33). Washington, DC: American Society of Microbiology, 2001.
12. Banerjee R, Leaver N, Lyster H et al. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc 2001; 33: 1600-1602.
13. Billaud EM, Guillemain R, Tacco F et al. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998; 46: 271-272.
14. Capone D, Gentile A, Imperatore P et al. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 1999; 33: 1124-1125.
15. Furlan V, Parquin F, Penaud JF et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 1998; 30: 187-188.
16. Outeda Macias M, Salvador P, Hurtado JL et al. Tacrolimus-itraconazole interaction in a kidney transplant patient. Ann Pharmacother 2000; 34: 536.
17. Wood N, Tan K, Allan R et al. Effect of voriconazole on the pharmacokinetics of tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16-19 December 2001 (abstract A-20). American Society of Microbiology: Washington, DC, 2001.
18. Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41: 381-388.
19. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999; 33: 680-682.
20. Schulman SL, Shaw LM, Jabs K et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation 1998; 65: 1397-1398.
21. Sheth SR, Hicks K, Ippoliti C et al. Safety, tolerability and drug interactions of adjuvant imatinib mesylate (Gleevec) within the first 100 days following stem cell transplantation (SCT) in patients with Ph + CML and Ph + ALL at high risk for recurrence. Blood 2002; 100: 635a (abstract 2500).
22. Gomez G, Alvarez ML, Errasti P et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. Transplant Proc 1999; 31: 2250-2251.
23. Wolter K, Wagner K, Philipp T et al. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994; 47: 207-208.
24. Jensen C, Jordan M, Shapiro R et al. Interaction between tacrolimus and erythromycin. Lancet 1994; 344: 825.
25. Shaeffer MS, Collier D, Sorrell MF. Interaction between FK506 and erythromycin. Ann Pharmacother 1994; 28: 280-281.
26. Padhi ID, Long P, Basha M et al. Interaction between tacrolimus and erythromycin. Ther Drug Monitor 1997; 19: 120-122.
27. McLaughlin GE, Rossique-Gonzalez M, Gelman B et al. Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. Transplant Proc 2000; 32: 665-668.
28. Thompson PA, Mosley CA. Tacrolimus-phenytoin interaction. Ann Pharmacother 1996; 30: 544.
29. Hebert MF, Fisher RM, March CL et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999; 39: 91-96.
30. Chenhsu RY, Loong CC, Chou MH et al. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother 2000; 34: 27-31.
31. Furlan V, Perello L, Jacquemin E et al. Interaction between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995; 59: 1217-1218.
32. Bolley R, Zulke C, Kammerl M et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 2002; 73: 1009-1010.
33. Boubenider S, Vincent I, Lambotte O et al. Interaction between theophylline and tacrolimus in a renal transplant patient. Nephrol Dial Transplant 2000; 15: 1066-1068.
34. Collignon P, Hurley B, Mitchell D. Interaction of fluconazole with cyclosporin. Lancet 1989; 1: 1262.
35. Tett S, Carey D, Lee HS. Drug interactions with fluconazole. Med J Austr 1992; 156: 365.
36. Sugar AM, Saunders C, Idelson BA et al. Interaction of fluconazole and cyclosporine. Ann Intern Med 1989; 110: 844.
37. Graves NM, Matas AJ, Hilligoss DM et al. Fluconazole/cyclosporine interaction. Clin Pharmacol Ther 1990; 47: 208.
38. Ehninger G, Jaschonek K, Schuler U et al. Interaction of fluconazole with cyclosporin. Lancet 1989; 2: 104-405.
39. Lucey MR, Kolars JC, Merion RM et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 1990; 335: 11-15.
40. Lopez-Gill JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother 1993; 27: 427-430.
41. Canafax DM, Graves NM, Hilligoss DM et al. Interaction between cyclosporin and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014-1018.
42. Kruger HU, Schuler U, Zimmermann R et al. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989; 24: 781-786.
43. Kramer MR, Marshall SE, Denning DW et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327-329.
44. Kwan JT, Foxall PJ, Davidson DG et al. Interaction of cyclosporin and itraconazole. Lancet 1987; 2: 282.
45. Romero AJ, Pogamp PL, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71: 226-234.
46. McCauley J, Ptachcinski RJ, Shapiro R. The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955-3957.
47. Lele P, Peteson P, Yang S et al. Cyclosporine and tegretol - another drug interaction. Kidney Int 1985; 27: 34.
48. Steinfort CL, McConachy KA. Cyclosporin-chloramphenicol drug interaction in a heart-lung transplant recipient. Med J Austr 1994; 161: 455.
49. Lum BL, Kaubisch S, Yahanda AM et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-1642.
50. McLellan RA, Drobitch RK, McLellan H et al. Norfloxacin interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995; 58: 322-327.
51. Hoey LL, Lake KD. Does ciprofloxacin interact with cyclosporine? Ann Pharmacother 1994; 28: 93-96.
52. Doose DR, Walker SA, Chien SC et al. Levofloxacin does not alter cyclosporine disposition. J Clin Pharmacol 1998; 38: 90-93.
53. Sadaba B, Lopez de Ocariz A, Azanza JR et al. Concurrent clarithromycin and cyclosporin A treatment. J Antimicrob Chemother 1998; 42: 393-395.
54. Spicer ST, Liddle C, Chapman JR et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997; 43: 194-196.
55. Harnett JD, Parfrey PS, Paul MD et al. Erythromycin-cyclosporine interaction in renal transplant recipients. Transplantation 1987; 43: 316-318.
56. Shipkova M, Armstrong VW, Kuypers D et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monitor 2001; 23: 717-721.
57. Schmidt H, Naumann R, Laschonek K et al. Drug interaction between cyclosporin and phenytoin in allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4: 212-213.
58. Keown PA, Laupacis A, Carruthers G et al. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 1984; 38: 304-306.
59. Freeman DL, Laupacis A, Keown PA et al. Evaluation of cyclosporine-phenytoin interaction with observations on cyclosporine metabolites. Br J Clin Pharmacol 1984; 18: 887-893.
60. Stamatakis MK, Richards JG. Interaction between quinupristin/dalfopristin and cyclosporine. Ann Pharmacother 1997; 31: 576-578.
61. Hebert MF, Roberts JP, Prueksaritanont T et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
62. Offerman G, Keller F, Molzahn M. Low cyclosporine A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5: 385-387.
63. Modry DL, Stinson EB, Oyer PE et al. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313-314.
64. Data on file. Wyeth Pharmaceuticals: Madison, NJ.
65. Christ B, Brockmeier D, Hauck EW et al. Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. Urology 2001; 58: 589-593.
66. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548-549.
67. Breidenbach TH, Kliem V, Burg M et al. Profound drop of cyclosporin A whole blood trough levels caused by St John's wort (Hypericum -perforatum). Transplantation 2000; 69: 2229-2230.
68. Barone GW, Gurley BJ, Ketel BL et al. Drug interaction between St John's wort and cyclosporine. Ann Pharmacother 2000; 34: 1013-1016.
69. Breidenbach T, Hoffmann MW, Becker T et al. Drug interaction of St John's wort with cyclosporin. Lancet 2000; 355: 1912.
70. Karliova M, Treichel V, Malago M et al. Interaction of Hypericum perforatum (St John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33: 853-855.
71. Mai I, Kruger H, Budde K et al. Hazardous pharmacokinetic interaction of St John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38: 500-502.
72. Mandelbaum A, Pertzborn F, Martin-Facklam M et al. Unexplained decrease of cyclosporine trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000; 15: 1473.
73. McAlister VC, Mahalati K, Peltekian KM et al. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 2002; 24: 346-350.
74. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995; 29: 619-624.
75. Nicolau DP, Crowe HM, Nightingale CH et al. Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother 1995; 29: 994-996.
76. Blum RA, Wilton JH, Hilligoss DM et al. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-425.
77. Cadle RM, Zenon GJ, Rodriguez-Barradas MC et al. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994; 28: 191-195.
78. Mitchell AS, Holland JT. Fluconazole and phenytoin: a predictable interaction. Br Med J 1989; 298: 1315.
79. Howitt KM, Oziemski MA. Phenytoin toxicity induced by fluconazole. Med J Austr 1989; 151: 603-604.
80. Crussell-Porter LL, Rindone JP, Ford MA et al. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Arch Intern Med 1993; 153: 102-104.
81. Black DJ, Kunze KL, Wienkers LC et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-428.
82. Baciewicz AM, Menke JJ, Bokar JA et al. Fluconazole-warfarin interaction. Ann Pharmacother 1994; 28: 1111.
83. Gericke KR. Possible interaction between warfarin and fluconazole. Pharmacotherapy 1993; 13: 508-509.
84. Yeh J, Soo SC, Summerton C et al. Potentiation of action of warfarin by itraconazole. Br Med J 1990; 301: 669.
85. Crane JK, Shih HT. Syncope and cardiac arrhythmia due to an interaction between itraconazole and terfenadine. Am J Med 1993; 95: 445-446.
86. Pohjola-Sintonen S, Viitasalo M, Toivonene L et al. Torsades de pointes after terfenadine-itraconazole interaction. Br Med J 1993; 306: 186.
87. Kamaluddin M, McNally P, Breatnach F et al. Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001; 90: 1204-1207.
88. Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 2001; 18: 137-142.
89. Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from drug interactions: case report and review of the literature. Pediatr Hematol Oncol 2001; 18: 543-546.
90. Bohme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995; 71: 311-312.
91. Murphy JA, Ross LM, Gibson BE. Vincristine toxicity in five children with acute lymphoblastic leukaemia. Lancet 1995; 346: 443.
92. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-485.
93. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56: 601-607.
94. Jalalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997; 61: 410-415.
95. Tucker RM, Denning DW, Hanson LH et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14: 165-174.
96. Bonay M, Jonville-Bera AP, Diot P et al. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf 1993; 9: 309-311.
97. Alderman CP, Allcroft PD. Digoxin-itraconazole interaction: possible mechanisms. Ann Pharmacother 1997; 31: 438-440.
98. Sachs MK, Blanchard LM, Green PJ. Interaction of itraconazole and digoxin. Clin Infect Dis 1993; 16: 400-403.
99. Rex J. Itraconazole-digoxin interaction. Ann Intern Med 1992; 116: 525.
100. Kauffman CA, Bagnasco FA. Digoxin toxicity associated with itraconazole therapy. Clin Infect Dis 1992; 15: 886-887.
101. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54-61.
102. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65.
103. Neuvonen PJ, Kantola T, Kivisto KJ. Simvastatin but not pravastatin is very susceptible to interactions with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-341.
104. Vlahakos DV, Manginas A, Chilidou D et al. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation 2002; 73: 1962-1964.
105. Ducharme MP, Slaughter RL, Warnasse LH et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 1995; 58: 617-624.
106. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998; 54: 155-158.
107. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994; 18: 266-267.
108. Smith JA, Hardin TC, Patterson TF et al. Rifabutin decreases itraconazole plasma levels in patients with HIV-infection (abstract). Second National Conference on Human Retroviruses and Related Infections, Washington DC, January 1995.
109. Glasmacher A, Hahn C, Molitor E et al. Definition of an itraconazole target concentration for antifungal prophylaxis. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17-20 September 2000 (abstract 700). American Society of Microbiology: Washington, DC, 2000.
110. Yule SM, Walker D, Cole M et al. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos 1999; 27: 417-421.
111. Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083-2088.
112. Data on file. Pfizer Inc.: New York, NY.
113. Ghahramani P, Purkins L, Kleinermans D et al. The pharmacokinetics of voriconazole and its effect on prednisolone disposition. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario 17-20 September 2000 (abstract 842). American Society of Microbiology: Washington, DC, 2000.
114. Ghahramani P, Purkins L, Kleinermans D et al. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17-20 September 2000 (abstract 844). American Society of Microbiology: Washington DC, 2000.
115. Ghahramani P, Purkins L, Kleinermans D et al. Voriconazole potentiates warfarin-induced prolongation of prothrombin time. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17-20 September, 2000 (abstract 846). American Society of Microbiology: Washington, DC, 2000.
116. Ghahramani P, Purkins L, Kleinermans DJ et al. Effect of omeprazole on the pharmacokinetics of voriconazole. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17-20 September 2000 (abstract 843). American Society of Microbiology: Washington, DC, 2000.
117. Wood N, Tan K, Allan R et al. Effect of voriconazole on the pharmacokinetics of omeprazole. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16-19 December 2001 (abstract A-19). American Society of Microbiology: Washington, DC, 2001.
118. Ghahramani P, Purkins L, Love ER et al. Drug interactions between voriconazole and phenytoin. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17-20 September 2000 (abstract 847). American Society of Microbiology: Washington, DC, 2000.
119. Kehrer DF, Mathijssen RH, Verweij J et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20: 3122-3129.
120. Stone JA, McCrea JB, Wickersham PJ et al. A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, 17-20 September 2000 (abstract 854). American Society of Microbiology: Washington, DC, 2000.
121. Data on file. Merck and Co.: Whitehouse Station, NJ.
122. Stone J, Holland S, Wickersham P et al. Drug interactions between caspofungin and tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 16-19 December 2001 (abstract A-13). American Society of Microbiology: Washington, DC, 2001.
123. Van Burik J, Ratanatharathorn V, Lipton J et al. Randomized, double-blind trial of micafungin (MI) versus fluconazole (FL) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG Protocol 46. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 27-30 September 2002 (abstract M-1238). Washington, DC: American Society of Microbiology, 2002.
124. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002; 62: 1481-1502.
125. Becquemont L, Verstuyft C, Kerb R et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70: 311-316.
126. Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933-942.
127. Honig PK, Wortham DC, Lazarev A et al. Pharmacokinetics and cardiac effects of terfenadine in poor metabolizers receiving concomitant grapefruit juice. Clin Pharmacol Ther 1995; 57: 185.
128. Rau SE, Bend JF, Tran LT et al. Inhibition of terfenadine metabolism by co-administration of grapefruit juice in humans. Clin Invest Med 1995; 18: 95.
129. Kupferschmidt HH, Ha HR, Ziegler WH et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-28.
130. Hukkinen SK, Varhe A, Olkkola KT et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995; 58: 127-131.
131. Vincent J, Harris SI, Foulds G et al. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol 2000; 50: 455-463.
132. Josefsson M, Ahlner J. Amlodipine and grapefruit juice. Br J Clin Pharmacol 2002; 53: 405.
133. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485-491.
134. Yee GC, Stanley DL, Pessa JL et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955-956.
135. Min DI, Ku YM, Perry PJ et al. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation 1996, 62: 123-125.
136. Brunner LJ, Munar MY, Vallian J et al. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy 1998; 18: 23-29.
137. Emilia G, Longo G, Bertesi M et al. Clinical interaction between grapefruit juice and cyclosporine: is there any interest for the hematologists? Blood 1998; 91: 362-363.
138. Ioannides-Demnos LL, Christophidis N, Ryan P et al. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol 1997; 24: 49-54.
139. McCauley J, Ptachcinski RJ, Shapiro R. The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955-3957.
140. Patton PR, Brunson ME, Pfaff WW et al. A preliminary report of diltiazem and ketoconazole. Their cyclosporine sparing effect and impact on transplant outcomes. Transplantation 1994; 57: 889-892.
141. Martin JE, Daoud AJ, Schroeder TJ et al. The clinical and economic potential of cyclosporin drug interactions. Pharmacoeconomics 1999; 15: 317-337.
142. Crone CC, Wise TN. Survey of alternative medicine use among organ transplant patients. J Transplant Coord 1997; 7: 123-130.
143. Eisenberg DM, Davis RB, Ettner SL. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280: 1569-1575.
144. Linde K, Ramirez G, Mulrow CD et al. St John's wort for depression: an overview and meta-analysis of randomised clinical trials. Br Med J 1996; 313: 253-258.
145. Mathijssen RH, Verweij J, de Bruijn P et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-1249.